Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.77-0.03 (-0.44%)
At close: 09:30AM EDT
Advertisement

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
908 517 7330
https://www.cyclacel.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Spiro George RombotisPres, CEO & Exec. Director839.53kN/A1959
Mr. Paul McBarronExec. VP of Fin., CFO, COO, Sec. & Exec. Director444.86kN/A1961
Dr. Mark H. Kirschbaum M.D.Sr. VP & Chief Medical Officer531.58kN/A1961
Ms. Gill ChristieDirector of HRN/AN/A1957
Dr. Robert Westwood Ph.D.Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.N/AN/A1944
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Corporate Governance

Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement